Jefferies Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $46M | Sell |
172,100
-29,700
| -15% | -$6.31M | 0.38% | 44 |
|
|
2022
Q2 | $41.2M | Buy |
201,800
+110,700
| +122% | +$22.6M | 0.34% | 49 |
|
|
2022
Q1 | $19.2M | Sell |
91,100
-62,700
| -41% | -$13.6M | 0.12% | 130 |
|
|
2021
Q4 | $36.9M | Buy |
153,800
+41,100
| +36% | +$10.6M | 0.22% | 69 |
|
|
2021
Q3 | $31.9M | Buy |
112,700
+60,000
| +114% | +$19.7M | 0.23% | 64 |
|
|
2021
Q2 | $18.2M | Sell |
52,700
-161,900
| -75% | -$49M | 0.11% | 141 |
|
|
2021
Q1 | $60M | Buy |
214,600
+197,600
| +1,162% | +$53.3M | 0.53% | 25 |
|
|
2020
Q4 | $4.16M | Buy |
17,000
+13,200
| +347% | +$3.41M | 0.03% | 471 |
|
|
2020
Q3 | $1.08M | Hold |
3,800
| – | – | 0.01% | 774 |
|
|
2020
Q2 | $1.02K | Sell |
3,800
-66,200
| -95% | -$19.9M | 0.01% | 750 |
|
|
2020
Q1 | $22.1M | Sell |
70,000
-9,400
| -12% | -$2.85M | 0.25% | 59 |
|
|
2019
Q4 | $23.6M | Buy |
79,400
+15,100
| +23% | +$4.19M | 0.18% | 89 |
|
|
2019
Q3 | $15M | Buy |
64,300
+9,000
| +16% | +$2.1M | 0.12% | 119 |
|
|
2019
Q2 | $12.9M | Buy |
55,300
+54,700
| +9,117% | +$12.6M | 0.09% | 169 |
|
|
2019
Q1 | $142K | Sell |
600
-1,100
| -65% | -$346K | ﹤0.01% | 2031 |
|
|
2018
Q4 | $512K | Sell |
1,700
-71,900
| -98% | -$22.9M | ﹤0.01% | 1455 |
|
|
2018
Q3 | $26M | Buy |
73,600
+70,100
| +2,003% | +$24.1M | 0.17% | 93 |
|
|
2018
Q2 | $1.02M | Sell |
3,500
-28,500
| -89% | -$8.01M | 0.01% | 1255 |
|
|
2018
Q1 | $8.76M | Buy |
32,000
+25,200
| +371% | +$7.82M | 0.05% | 289 |
|
|
2017
Q4 | $2.17M | Sell |
6,800
-6,300
| -48% | -$2.02M | 0.01% | 959 |
|
|
2017
Q3 | $4.1M | Sell |
13,100
-3,100
| -19% | -$918K | 0.03% | 613 |
|
|
2017
Q2 | $4.4M | Buy |
16,200
+8,700
| +116% | +$2.3M | 0.03% | 593 |
|
|
2017
Q1 | $2.05M | Sell |
7,500
-100,000
| -93% | -$28.3M | 0.02% | 901 |
|
|
2016
Q4 | $30.5M | Buy |
107,500
+53,500
| +99% | +$15.9M | 0.17% | 88 |
|
|
2016
Q3 | $16.9M | Buy |
54,000
+34,800
| +181% | +$10.3M | 0.09% | 182 |
|
|
2016
Q2 | $4.64M | Buy |
19,200
+18,600
| +3,100% | +$4.9M | 0.02% | 517 |
|
|
2016
Q1 | $156K | Sell |
600
-48,100
| -99% | -$12.7M | ﹤0.01% | 1898 |
|
|
2015
Q4 | $14.9M | Sell |
48,700
-13,900
| -22% | -$3.99M | 0.08% | 186 |
|
|
2015
Q3 | $18.3M | Buy |
62,600
+47,100
| +304% | +$15.6M | 0.1% | 152 |
|
|
2015
Q2 | $6.26M | Buy |
+15,500
| New | +$6.22M | 0.03% | 424 |
|
|
2014
Q3 | – | Sell |
-30,000
| Closed | -$9.46M | – | 2137 |
|
|
2014
Q2 | $9.46M | Buy |
30,000
+25,500
| +567% | +$7.67M | 0.08% | 217 |
|
|
2014
Q1 | $1.38M | Buy |
+4,500
| New | +$1.43M | 0.01% | 766 |
|
Other funds holding BIIB
Jefferies Group's BIIB Position: Q3 2022 in Review
Jefferies Group reduced its Biogen (BIIB) stake by 100% in Q3 2022, selling an estimated $12.2M and leaving 50 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1553.
Jefferies Group first reported a position in BIIB in Q3 2013 and has held it in 36 quarters since. The position peaked at $41.4M in Q3 2016. 986 funds tracked by Wall St. Rank hold BIIB as of Q3 2022.
- Jefferies Group held 50 shares of Biogen worth $13.3K as of Q3 2022.
- Jefferies Group sold 57,549 Biogen shares in Q3 2022, an estimated $12.2M.
- Biogen made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1553 holding.
- Jefferies Group first reported a position in Biogen in Q3 2013 and has held it in 36 quarters since.
- Jefferies Group's Biogen position peaked at $41.4M in Q3 2016.
- 986 funds tracked by Wall St. Rank held Biogen as of Q3 2022.
Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.